BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Robert Baffi sold 18,415 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $92.43, for a total value of $1,702,098.45. Following the completion of the sale, the executive vice president now owns 129,083 shares of the company’s stock, valued at approximately $11,931,141.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 93.20 on Thursday. BioMarin Pharmaceutical Inc. has a 52-week low of $78.42 and a 52-week high of $100.51. The firm’s 50-day moving average price is $89.07 and its 200-day moving average price is $89.65. The stock’s market capitalization is $16.33 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The company had revenue of $317.50 million for the quarter, compared to analysts’ expectations of $311.41 million. During the same period last year, the firm earned ($2.61) EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($0.71) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/insider-selling-biomarin-pharmaceutical-inc-bmrn-evp-sells-1702098-45-in-stock.html.

Hedge funds have recently modified their holdings of the company. Parallel Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 13.6% during the 1st quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 125 shares during the period. Korea Investment CORP increased its position in shares of BioMarin Pharmaceutical by 143.5% during the 2nd quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 940 shares during the period. Global X Management Co. LLC increased its position in shares of BioMarin Pharmaceutical by 59.7% during the 1st quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 619 shares during the period. Mutual of America Capital Management LLC increased its position in shares of BioMarin Pharmaceutical by 20.0% during the 1st quarter. Mutual of America Capital Management LLC now owns 2,066 shares of the biotechnology company’s stock valued at $181,000 after purchasing an additional 344 shares during the period. Finally, Toronto Dominion Bank increased its position in shares of BioMarin Pharmaceutical by 12.9% during the 2nd quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 243 shares during the period. Institutional investors own 97.47% of the company’s stock.

A number of equities research analysts have weighed in on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 26th. Piper Jaffray Companies began coverage on BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued an “overweight” rating and a $113.00 target price on the stock. ValuEngine raised BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Royal Bank Of Canada began coverage on BioMarin Pharmaceutical in a report on Thursday, September 14th. They issued a “sector perform” rating and a $93.00 target price on the stock. Finally, BMO Capital Markets reissued a “buy” rating on shares of BioMarin Pharmaceutical in a report on Friday, September 15th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $109.09.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.